In the past 10 to 20 years, there has been accumulating evidence that infection with Epstein-Barr virus (EBV) and inadequate vitamin D nutrition increase multiple sclerosis (MS) risk. 1, 2 The natural next step is to understand whether and how EBV and vitamin D may influence each other's effect on MS: can one factor either fully or partially explain the effects of the other? Do they interact such that their joint effect on MS risk is greater than (or less than) the sum of their individual effects (relative risk additive on the logscale)? Because EBV infection is nearly universal, most studies on EBV have relied on measuring circulating titers of antibodies to the EBV nuclear antigen-1 (anti-EBNA-1), which, when measured in healthy young adults, have been demonstrated to be strongly and monotonically associated with an increased risk of developing MS. 2 Are the anti-EBNA-1 IgG titers correlated with vitamin D status and does the latter explain or modify the relation between these titers and MS risk?
In this issue of Multiple Sclerosis Journal, Salzer et al. 3 address these questions in a case-control study nested within a prospective cohort of 164,000 Swedish individuals (92% women). They previously reported that elevated serum levels of 25-hydroxyvitamin D (25(OH)D) were associated with a reduced risk of MS in this population. 4 In the current study, Salzer et al. confirm that high pre-MS onset levels of EBNA-1 IgG antibody titers are associated with an increased risk of MS, extend this finding to antibody titers against specific EBNA-1 epitopes, and demonstrate that this association is not confounded by levels of 25(OH)D-that is, after adjusting for serum levels of 25(OH)D, the risk of MS associated with high EBNA-1 IgG titer levels did not change. Further, while they found a weak to moderate inverse correlation between levels of EBNA-1 IgG antibody titers and 25(OH)D (in individuals less than 26.4 years old: r=−0.13, p=0.03; <20 years old: r=−0.35, p<0.01), there was no evidence of a statistical interaction between EBV and 25(OH)D-that is, their joint effect on MS risk was not different from the sum of their individual effects on MS risk. These findings are consistent with two previous studies, one in the US military cohort, 5 and one in Canadian children, 6 both of which also found no evidence for confounding or a statistical interaction between levels of EBNA-1 IgG antibody titers and 25(OH)D in determining MS risk. Collectively, these studies provide evidence that anti-EBNA-1 IgG titers and inadequate vitamin D nutrition are statistically independent risk factors for MS.
In their Letter to the Editor, also in this issue of Multiple Sclerosis Journal, Disanto et al. 7 report the results of a small uncontrolled study examining anti-EBNA-1 titers in 15 patients with relapsing-remitting MS before and after supplementation with 20,000 IU of vitamin D3 per day over a period of 12 weeks. Mean EBNA-1 antibody titers were found to be lower after the supplementation period (p=0.02), and this association was stronger in MS patients with the highest EBNA-1 IgG antibodies. Despite the different study populations and the supraphysiological doses of vitamin D given, the authors conclude that their results suggest that the negative correlation between vitamin D status and circulating antibody levels against EBV observed by Salzer et al. may be due to an effect of vitamin D on the immune response to EBV. It should be noted, however, that because of the lack of a control group, the results of the study by Disanto et al. suggest, but do not demonstrate, an effect of vitamin D on anti-EBNA-1 titers; further, the presumed stronger effect in individuals with higher anti-EBNA-1 titers is consistent with a regression to the mean, and should thus be interpreted very cautiously. These limitations notwithstanding, an effect of vitamin D status on the immune response to EBV remains an intriguing hypothesis, which is worth exploring in future investigations.
The lack of confounding and of a detectable interaction between vitamin D and EBV suggests that they are largely independent risk factors for MS-that is, elevated anti-EBNA-1 IgG titers are a risk factor for MS even among individuals who are vitamin D sufficient, and, conversely, vitamin D insufficiency is a risk factor for MS in individuals with low anti-EBNA-1 titers. From a prevention point of view, these observations suggest that in the absence of a way to prevent EBV infection, increasing vitamin D levels remains the primary strategy to reduce MS risk.
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